Abstract. The clinical significance of NK-like T CD3
+ / CD16 + CD56 + cells in chronic lymphocytic leukemia (CLL) is still a subject of controversy. There are few previous descriptions that this cell population can be qualitatively or quantitatively deficient in CLL patients. In the present study we investigated the clinical value of CD3 + /CD16 
Introduction
Chronic lymphocytic leukemia (CLL) which is the most common leukemia of adults in Western countries still remains incurable. It follows an extremely variable course with survival from months to decades. Studies on the novel prognostic factors in CLL are essential for improvement of criteria for starting the cytostatic treatment. Besides Rai or Binet staging system, some chromosomal aberrations, in particular concerning 11q and 17p, IgV H mutational status, as well as CD38 and ZAP-70 expression, are currently considered as the most important prognostic factors as to progression-free and overall survival (1) . The issue of defining of unfavorable prognostic factors which may give reason for the early beginning, i.e. before the meeting of the currently admitted criteria, of cytostatic treatment, needs further studies. Current prognostic factors (i.e. IgV H mutational status, ZAP-70, CD38) concentrate on the intrinsic abnormalities of the malignant B cell clone (2) (3) (4) . However, it became clear that transformation and progression of tumors is not an independent process but it is controlled by their interactions with the tumor microenvironment (5) . Probably interactions between the leukemic cells and native immune system could have an important influence on disease progression. There are three main lymphocyte subsets that play important roles in the regulation of immune responses to pathogens as well as to tumors: conventional T lymphocytes, natural killer (NK) cells and the third lymphocyte subset referred as natural killer T (NKT) cells (6) . It has been shown that T cell dysfunctions account for pathological conditions such as increased susceptibility to infections, autoimmune hemolytic anaemia, and hypo-gammaglobulinemia, commonly noted in CLL patients. The changes in number and functions of T lymphocytes may support the 'microenvironment' that sustains the malignant B cells clone, delays their apoptosis and may contribute to the pathogenesis and progression of the disease (7) (8) (9) . Likewise, the phenotypic and functional abnormalities found in NK cells, such as defective cytotoxic activity, might allow the appearance and maintenance of leukemic B cells accumulation. A dilutional effect of leukemic B cells and intrinsic (21, 22) . This cell population can be highly expanded in vitro by the addition of the cytokines (IFN-Á, IL-1, IL-2) and anti-CD3 monoclonal antibody. These CD3 + CD56 + cells have been termed cytokine-induced killer cells (CIK cells) and it was shown that they possess enhanced cytotoxicity against various tumor cells (23). In contrast to NK-like T cells that are de novo, CIK cells are generated following in vitro culturing (24, 25 (27, 28) . To our knowledge, this is the first study of this cell population investigating the relationship between the peripheral blood CD3 + /CD16 + CD56 + cells and clinical outcome in newly diagnosed patients with CLL. In the current study, for the first time, we present this cell population frequencies in the CLL bone marrow.
Materials and methods
Patients and samples. Peripheral blood (PB) and bone marrow (BM) specimens were obtained from 300 untreated CLL patients diagnosed between September 1997 and December 2008 (187 men and 113 women). The median age of patients was 66 years (ranging from 32 to 87 years). CLL diagnosis based on a clinical examination, morphological and immunological criteria (29) . At the time of diagnosis, patients were staged according to the Rai staging system (30) as follows: stage 0 (92 cases), stage 1 (57 cases), stage 2 (69 cases), stage 3 (40 cases) and stage 4 (42 cases). One hundred and thirty-one patients (43.7%) with stable disease did not receive chemotherapy, and 169 patients (56.3%) with progressive disease required treatment. The patients cohort was divided into three groups: patients with Rai stage 0 (92 cases), stage 1-2 (126 cases) and stage 3-4 (82 cases). The control samples consisted of PB from 20 healthy volunteers (8 men and 12 women aged from 33 to 66 years, median age of 58 years) and BM from 10 healthy donors. PB and BM samples were collected into heparinized tubes and immediately processed. The study was approved by the Local Ethics Committee. Peripheral blood and bone marrow samples were obtained from the patients and healthy volunteers after informed consent.
Assessment of CD3
+ /CD16 + CD56 + cells. Immunophenotypic analysis is a key adjunctive tool for diagnosis of chronic lymphocytic leukemia and is typically performed by flow cytometry (29) . The primary purpose of such analysis is to look for the immunophenotypic pattern that is characteristic for leukemic cells in CLL. In our study the standard diagnostic flow cytometric analysis included also monoclonal antibodies (MoAbs) anti-CD3 FITC/CD16 + CD56 PE/CD45 PerCP (BD Biosciences) which permitted simultaneous assessment of T (CD3 + ) lymphocytes and NK (CD16 + CD56 + ) cells. During analysis, CD3 + /CD16 + CD56 + population was determined. A standard, whole-blood assay with erythrocyte cell lysis was used for preparing the PB or BM specimens. The samples were analyzed by flow cytometry directly after preparation. For data acquisition and analysis, a FACS Calibur instrument (BD) with CellQuest software (BD) was used. For each analysis 10,000 events were acquired and analyzed. The percentage of positive cells was measured from a cutoff set using isotype matched non-specific control antibody. 
Analysis of ZAP-70 expression in CLL cells.
All PB samples were stained for ZAP-70 protein expression. We used a modification of a previously described method for flow cytometric examination of ZAP-70 protein expression (31) . A cut-off point for ZAP-70 positivity in leukemic cells was ≥20%.
Detection of CD38 expression. Flow cytometry analysis of CD38 antigen expression was performed on fresh PB samples, as described previously (32) . CLL cells were considered CD38-positive when ≥20% of them expressed the membrane antigen.
Analysis of LPL and ADAM29 expression in CLL cells.
Peripheral blood samples from 100 CLL patients were stained for LPL and ADAM29 expression. We used a previously described method for flow cytometric examination of LPL and ADAM29 expression (33) .
Intracellular IFN-Á, TNF, IL-10 and IL-4 staining. In 25 CLL patients we examined an intracellular IFN-Á and IL-4 expression by CD3
+ CD56 + cells. Intracellular TNF analysis was performed on fresh PB or BM samples, as described previously (34) . MoAbs used for analyses included anti-CD3 FITC (BD PharMingen), anti-CD56 CyChrome (BD PharMingen) and anti-TNF PE (BD Biosciences), anti-IFN-Á PE (BD Biosciences), anti-IL-4 (BD Biosciences) and anti-IL-10 PE (BD PharMingen). In the experiment, the mean percentages of CD3 + CD56 + cells with intracellular cytokine expression were analyzed.
Statistical analysis. Differences between two groups were assessed using the U Mann-Whitney test. The Wilcoxon paired test was used to compare the results in peripheral blood and bone marrow. The Spearman rank correlation coefficient was used in correlation tests. The Kaplan-Meier method was used for drawing survival curves, and results were compared using the log-rank test. The treatment free survival (TFS) was calculated from the date of diagnosis to the date of first treatment. We used Statistica 7.0 PL software for all statistical procedures. Differences were considered statistically at p≤0.05. (Fig. 3) . Similarly, there was a tendency for higher frequencies of CD3 + /CD16 + CD56 + cells in patients who were CD38 negative (5.51 vs. 4.74%, p=0.005) (Fig. 4) . In the present study we found a significant positive correlation between LPL and ZAP-70 expression (R=0.261; p=0.037) as well as between LPL and CD38 expression (R=0.227; p=0.032). Next, the analysis of survival curves in both groups was performed only in early stages (Rai stage 0). However, due to the lack of deceased cases, only the assessment of TFS was possible. (Table II) .
Results
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Discussion
It is known that patients suffering from hematopoietic malignancies are under immunosuppressive conditions induced by increasing tumor cells and administration of chemotherapy. A previous study showed a reduced number of ONCOLOGY REPORTS 24: 803-810, 2010 807 Table I . Median percentage of CD3 + CD56 + cells with intracellular TNF, IFN-Á, IL-4 and IL-10 expression in peripheral blood from CLL patients and health controls. ------------------------------------------------ 
The U Mann-Whitney test was applied for a statistical comparison of the results between CLL patients and healthy controls. a p-value of <0.05 was considered statistically significant. Table II . Median percentage of CD3 + CD56 + cells with intracellular TNF, IFN-Á, IL-4 and IL-10 expression in peripheral blood and bone marrow from ZAP-70 + and ZAP-70 -patients. 
The CLL population was considered ZAP-70 positive when at least 20% of CD19 + /CD5 + cells were positive for ZAP-70, as assessed by flow cytometry. The p-value was calculated using the U Mann-Whitney test.
a p-value of <0.05 was considered statistically significant.
-
peripheral V·24 + NKT cells in the patients with a variety of hematopoietic malignancies in comparison with that in healthy donors (35) . However, there has been few previous descriptions that NKT cells can be qualitatively or quantitatively deficient in CLL patients. Fais et al (11) suggested that number of NKT cells in CLL patients is low. Guven et al (10) reported the possibility of expanding of CD3 + CD56 + cell population, from peripheral blood mononuclear cells of CLL patients. The expansion rates were lower for the patients with progressive disease (10) As bone marrow NKR + T cells have been postulated to play a role in tumor surveillance (36), next we assessed the CD3 + /CD16 + CD56 + number in BM aspirates. Bone marrow examination is not generally essential for the diagnosis of CLL, it is important for determination of the course of cytopenias and evaluation of the response to therapy (37) . CLL bone marrow is invariably infiltrated with leukemic cells, and the extent of infiltration correlates with the clinical stage and prognosis (37) (38) (39) . It can support a diagnosis of CLL showing atypical morphology and exclusively allows the assessment of the infiltration type (diffuse vs. non-diffuse) (37) . In addition to hematopoietic progenitor cells, bone marrow contains phenotypically and functionally mature T and NK cells (36) . The presence of such cells may be important in fighting malignancy, as both cell types are known to play a role in the attack on cancerous cells (36 + cells with intracellular IFN-Á and TNF expressions in CLL patients compared to healthy controls. Changes in the cytokine network could sustain the expansion of the leukemic B-cell clone. The explanation of abnormalities in the circulating non-malignant immune cells of CLL patients offers important insights into the biology of the disease. In the current study, ZAP-70-positive patients showed lower percentages of CD3 + CD56 + cells with IFN-Á or TNF expression. These cytokines are necessary for potentiation of the cytotoxic activity of T cells and NK cells (41) , and decreased synthesis of these cytokines is the potential reason of impaired cytotoxic function. Furthermore, both IFN-Á and TNF possess direct cytotoxic and cytostatic activity toward tumor cells and are involved in anticancer response (42, 43) . A reduced number of CD3 + CD56 + cells expressing intracellular IFN-Á or TNF might represent a risk factor for the progression of disease. Different data exist on IFN-Á production by NKT cells. Some investigators showed that invariant NKT cells in cancer patients are functionally impaired and produce less IFN-Á (44) while others established that iNKT cells are functionally normal (45) and have a preserved production of IFN-Á (46). We also examined IL-4 and IL-10 expression by CLL CD3 + CD56 + cells. In the patients population the percentage of CD3 + CD56 + cells with intracellular IL-10 expression was higher than in healthy individuals. The combination of IL-4 and IL-10 is able to suppress the generation of IFN-Á producting cells (47) . These result suggests that tracking the frequency and function of NKT-like cells could contribute to the understanding of disease pathogenesis. Because CD56 + T cells can produce Th1-type and Th2-type cytokines (18) 
